NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Therapeutic Vaccine for HIV

Phase 1

Completed

Conditions: HIV
Therapeutic Vaccine

Interventions: Drug: Placebo
Biological: rVSV
Biological: IL-12 pDNA adjuvant
Biological: HIV-Mag pDNA

First Posted Date: 2013-05-21

Last Posted Date: 2020-03-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 33

Registration Number: NCT01859325

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen

Phase 2

Terminated

Conditions: Kidney Transplantation
Primary Renal Allograft Candidate

Interventions: Biological: Anti-thymocyte Globulin (Rabbit)
Biological: belatacept
Drug: methylprednisolone
Biological: basiliximab
Drug: mycophenolate mofetil
Drug: tacrolimus

First Posted Date: 2013-05-17

Last Posted Date: 2020-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 71

Registration Number: NCT01856257

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States

Idebenone for Primary Progressive Multiple Sclerosis

Phase 1

Completed

Conditions: Multiple Sclerosis
Primary Progressive Multiple Sclerosis

Interventions: Drug: Idebenone

First Posted Date: 2013-05-15

Last Posted Date: 2021-05-19

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 61

Registration Number: NCT01854359

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Sildenafil for PNTM Infection

Phase 1

Completed

Conditions: Nontuberculous Mycobacterial Infection

First Posted Date: 2013-05-15

Last Posted Date: 2015-09-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT01853540

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

Phase 1

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: RSV cps2 Vaccine
Biological: Placebo Vaccine

First Posted Date: 2013-05-13

Last Posted Date: 2016-09-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 50

Registration Number: NCT01852266

Locations: 🇺🇸
Johns Hopkins University, Center for Immunization Research (CIR), Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University, Center for Immunization Research South, Laurel, Maryland, United States

Radiofrequency Ablation for Liver Abscesses From Chronic Granulomatous Disease

Phase 1

Withdrawn

Conditions: Chronic Granulomatous Diseases (CGD) and Liver Lesions

Interventions: Device: Cool-tip RF Ablation System

First Posted Date: 2013-05-10

Last Posted Date: 2020-03-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT01851460

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Bone Marrow Stromal Cells for Inflammatory Bowel Diseases

Phase 1

Terminated

Conditions: Inflammatory Bowel Disease

Interventions: Other: Bone Marrow Stromal Cell (BMSC) Infusion

First Posted Date: 2013-05-10

Last Posted Date: 2019-03-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 8

Registration Number: NCT01851343

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Human Rhinovirus Infection and Airway Remodeling Mediators

Not Applicable

Terminated

Conditions: Asthma

Interventions: Biological: GMP-grade HRV-39
Procedure: Bronchoalveolar Lavage
Drug: Methacholine Inhalation Challenge
Procedure: Nasal Lavage
Procedure: Nasal Scrapings
Procedure: Bronchial Brushings
Procedure: Lung Mucosal Biopsy
Procedure: Allergen Skin Prick Testing
Procedure: Venipuncture
Procedure: Bronchoscopy
Procedure: Spirometry

First Posted Date: 2013-05-07

Last Posted Date: 2015-08-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 2

Registration Number: NCT01847768

Locations: 🇨🇦
University of Calgary, Calgary, Alberta, Canada

Rituximab for Anti-cytokine Autoantibody-Associated Diseases

Phase 1

Completed

Conditions: Pulmonary Alveolar Proteinosis (PAP)
Severe Mucocutaneous Candidiasis

Interventions: Drug: Rituximab

First Posted Date: 2013-04-29

Last Posted Date: 2025-06-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 7

Registration Number: NCT01842386

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Malaria Transmission Studies in Mali

Completed

Conditions: Malaria, Falciparum

First Posted Date: 2013-04-11

Last Posted Date: 2018-08-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 534

Registration Number: NCT01829737

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy